AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26852095
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) combined with maintenance antidepressant medication (mADM)
Trial: 26852095
Drug: Maintenance antidepressant
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance antidepressant medication (mADM)
Trial: 19671565
Drug: Injection Troynoxa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection Troynoxa (enoxaparin sodium 40 mg/0.4 mL)
Trial: 19671565
Drug: Injection Clexane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection Clexane (enoxaparin sodium 40 mg/0.4 mL)
Trial: 12190161
Drug: Midazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2 mg <70 kg b.w. or 3 mg >70 kg b.w.) and propofol (median dose 80 mg, range 40-150)
Trial: 12190161
Drug: Midazolam (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (median dose 5 mg, range 3-7) and pethidine (75 mg, range 50-125)
Trial: 9973029
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with heparin (5,000 U bolus, 1,000 to 1,300 U/h infusion)
Trial: 9973029
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with hirudin (0.1 to 0.6 mg/kg bolus, 0.1 to 0.2 mg/kg/h infusion)
Trial: 9973029
Drug: Intensity of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity of anticoagulation (heparin or hirudin)
Trial: 26709238
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch 10 mg/16 hr for 8 weeks
Trial: 26709238
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch 15 mg/16 hr for 8 weeks
Trial: 22654429
Drug: 7-day conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day conventional triple therapy
Trial: 22654429
Drug: 10-day conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day conventional triple therapy
Trial: 22654429
Drug: 14-day conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day conventional triple therapy
Trial: 19464125
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone (HYD) 12 mg IM
Trial: 19464125
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone (HYD) 24 mg IM
Trial: 17364587
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of olmesartan (20 mg)
Trial: 17364587
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of olmesartan (20 mg)
Trial: 15164513
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antianginal drugs and membran‐oprotective drugs (MPD)
Trial: 15164513
Drug: Antianginal drugs
RxNorm normalized name: ANTIANGINALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antianginal drugs alone
Trial: 11136274
Drug: naproxen (500-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen (500-1000 mg/day) and misoprostol (200 microg b.d.)
Trial: 11136274
Drug: nabumetone (1000-1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nabumetone (1000-1500 mg/day) and placebo misoprostol
Trial: 2927553
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase with 5 X 10(5) IU (SK‐i.v.) in group A before transport
Trial: 2927553
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase with 5 X 10(5) IU (SK‐i.v.) in group B after transport
Trial: 30894394
Drug: Self-injection training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-injection training for DMPA-SC
Trial: 28219801
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) - 10 cycles, using DIOMED Light or PhotoDYN Light
Trial: 21681863
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (TAPS)
Trial: 16378915
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea capsules
Trial: 12946074
Drug: Silica-coated ceramic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silica-coated ceramic surface with Panavia 21 and silane/bonding agent
Trial: 12946074
Drug: Untreated ceramic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated ceramic surface with Panavia 21 and silane/bonding agent
Trial: 11776174
Drug: One antibiotic
RxNorm normalized name: Neomycin Sulfate 3.5 mg in 1 g / Polymyxin B Sulfate 10000 [iU] in 1 g / Pramoxine Hydrochloride 10 mg in 1 g TOPICAL CREAM [CAREONE Antibiotic Plus Pain Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One antibiotic given for three days (group B)
Trial: 11776174
Drug: Only once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Only once antibiotic used (group C)
Trial: 11776174
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic given (group A)
Trial: 11776174
Drug: Both cesarean
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both cesarean section and antibiotics
Trial: 8383058
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg x 2 (in reference group)
Trial: 8383058
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg x 2
Trial: 8383058
Drug: Morphine 5
RxNorm normalized name: ethylmorphine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 5 mg x 3
Trial: 3087862
Drug: Interferon (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (5 X 10(6) IU) administered once daily subcutaneously during a five day treatment period followed by a three month maintenance period (1 X 10(6) IU three times weekly)
Trial: 23292622
Drug: Buspirone (20-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (20-30 mg/day depending on weight)
Trial: 15699292
Drug: DHEA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA therapy (90 mg/d for 3 weeks and 450 mg/d for 3 weeks)
Trial: 18425654
Drug: Tobacco cessation
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco cessation intervention delivered by dental hygienists during cleaning visits; specific components included video and written materials; details on dosage and duration not specified.
Trial: 1717688
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release formulation of tiaprofenic acid (two 300 mg capsules once a day)
Trial: 1717688
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation of tiaprofenic acid (one 300 mg tablet taken twice a day)
Trial: 17917317
Drug: Valsartan (40‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (40‐80 mg/day)
Trial: 17917317
Drug: Nifedipine (20‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20‐40 mg/day)
Trial: 9620489
Drug: Topical agent
RxNorm normalized name: topical agent combination no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agent
Trial: 7882454
Drug: Oral amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amiodarone (600-800 mg daily) with infusional doxorubicin (60 mg/m2 over 96 h)
Trial: 7882454
Drug: Oral amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amiodarone (600-800 mg daily) with infusional vinblastine (8.5 mg/m2 over 120 h)
Trial: 2142915
Drug: Ipratropium (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium (80 micrograms via metered dose inhaler with each salbutamol treatment, 6 to 8 times per day)
Trial: 2142915
Drug: Placebo (via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (via metered dose inhaler with each salbutamol treatment, 6 to 8 times per day)
Trial: 30316635
Drug: <350 mg/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <350 mg/dL (moderate control)
Trial: 30316635
Drug: <600 mg/dL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <600 mg/dL (loose control)
Trial: 26083474
Drug: 10-Valent Pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-Valent Pneumococcal Non-Typeable Haemophilus influenza Protein D Conjugate Vaccine (PHiD-CV)
Trial: 11332239
Drug: Rofecoxib (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (maximum single dose 12.5 mg, cumulative dose 25 mg)
Trial: 7889606
Drug: Percutaneous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous ethanol injection after fine needle aspiration (Group 2)
Trial: 7889606
Drug: Percutaneous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous ethanol injection (Group 3)
Trial: 7889606
Drug: Percutaneous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous ethanol injection (Group 2)
Trial: 12855921
Drug: Transdermal ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal ketoprofen applied TID to quadriceps
Trial: 12855921
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied TID to quadriceps
Trial: 10911654
Drug: Icodextrin (I)
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icodextrin (I) solution
Trial: 10911654
Drug: Icodextrin (I)
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icodextrin (I) solution during peritonitis (P)
Trial: 10911654
Drug: Glucose (G)
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose (G) solution
Trial: 10911654
Drug: Glucose (G)
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose (G) solution during peritonitis (P)
Trial: 8616558
Drug: Aerosolized bronchodilator
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized bronchodilator
Trial: 6088396
Drug: Fresh human
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh human milk (200 ml per day)
Trial: 24659069
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation (IVS) with midazolam/fentanyl
Trial: 20097931
Drug: Tocilizumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (4 or 8 mg/kg)
Trial: 9145453
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (untreated controls)
Trial: 9145453
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of antioxidant vitamins
Trial: 18059393
Drug: Total antibiotic
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total antibiotic use
Trial: 18059393
Drug: Antibiotic use
RxNorm normalized name: Antibiotics for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic use by site
Trial: 18059393
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of antibiotic use
Trial: 18059393
Drug: Age at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age at first antibiotic use
Trial: 17044452
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination (ID group) - 10 microg of recombinant hepatitis B vaccine (Engerix B) intradermally every 2 weeks for a total of 7 doses.
Trial: 17044452
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination (IM group) - 40 microg intramuscularly at 0, 1, 2, and 6 months.
Trial: 17044452
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination (ID group)
Trial: 17044452
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination (IM group)
Trial: 12830437
Drug: Daily Hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Hemodialysis (n = 11)
Trial: 12830437
Drug: Conventional Thrice-Weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Thrice-Weekly Hemodialysis (Control)
Trial: 1583246
Drug: ICI 204,219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 204,219 (40 mg)
Trial: 26608342
Drug: Non-alcohol antimicrobial
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-alcohol antimicrobial mouth rinse containing cetylpyridinium chloride and oral health education
Trial: 26608342
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received a package of toothbrush and paste, plus oral hygiene education
Trial: 20568432
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (needles at Zusanli (ST 36), Zhongwan (CV 12), Weishu (BL 21), Neiguan (PC 6), once a day)
Trial: 20568432
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment (20 mg Omeprazole, once a day)
Trial: 12930517
Drug: L-E-GTF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-E-GTF
Trial: 12930517
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (L-E-GTF and Soluble E-GTF)
Trial: 15321259
Drug: Intravenous nalmefene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nalmefene 0.25 micro.kg(‐1) every 12 h x 2
Trial: 15321259
Drug: Intravenous nalmefene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nalmefene 0.5 microg.kg(‐1) every 12 h x 2
Trial: 15321259
Drug: Naloxone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone infusion 48 microg.h(‐1) (1.2 microg.ml(‐1))
Trial: 1738553
Drug: Antibiotic eardrops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic eardrops administered to right ears intraoperatively and for 3 days post-surgery
Trial: 1738553
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic eardrops (control) administered to left ears
Trial: 4006253
Drug: slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow release Nifedipine (srN) 20 mg b.d.
Trial: 4006253
Drug: slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow release Nifedipine (srN) 20 mg b.d. plus Acebutolol (A) 400 mg
Trial: 29635145
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment discontinuation
Trial: 18812115
Drug: 0.1 mL
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mL preservative‐free lidocaine hydrochloride 1% injected in the capsular bag during hydrodissection
Trial: 18812115
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution (BSS) (control group)
Trial: 12913083
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (PPC) with 5-FU (320 mg/m²/day for 5 days) and postoperative chemotherapy with MMC (6 mg/m²) and oral 5-FU (200 mg/day for 6 months)
Trial: 12913083
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (PC) with MMC (6 mg/m²) and oral 5-FU (200 mg/day for 6 months)
Trial: 12913083
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (PPC)
Trial: 12913083
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (PC)
Trial: 7572702
Drug: Dietary calcium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary calcium intake of 1768 mg/d (44 mmol/d)
Trial: 7572702
Drug: Halving daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halving daily sodium excretion
Trial: 7572702
Drug: Urinary sodium
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary sodium excretion
Trial: 7572702
Drug: Dietary calcium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary calcium intake and urine sodium excretion
Trial: 1951503
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg methylcellulose gel
Trial: 1951503
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg controlled-release pessary
Trial: 19684236
Drug: Strict glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict glucose control with predominantly meal related insulin using subcutaneous insulin
Trial: 19684236
Drug: Strict glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict glucose control with predominantly basal insulin using intravenous insulin
Trial: 19684236
Drug: Conventional glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucose lowering therapy
Trial: 19684236
Drug: Meal related
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal related insulin group
Trial: 19684236
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin group
Trial: 17454716
Drug: Naltrexone and
RxNorm normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone and nicotine patch
Trial: 31937442
Drug: Kinesiotaping in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesiotaping in addition to flurbiprofen 200 mg/day
Trial: 31937442
Drug: Flurbiprofen 200
RxNorm normalized name: flurbiprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 200 mg/day (Control)
Trial: 27623523
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of soft tissue and neural mobilization techniques
Trial: 25826649
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT) administration prior to exposure therapy
Trial: 17426195
Drug: Methylprednisolone infusion
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone infusion (1 mg/kg/d)
Trial: 1610632
Drug: i.v. fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. fluid 1000 ml
Trial: 1610632
Drug: ephedrine 24
RxNorm normalized name: ephedrine 24 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ephedrine 24 mg
Trial: 1610632
Drug: methoxamine 4
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methoxamine 4 mg
Trial: 6380281
Drug: Methadone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (2.5 or 5 mg) + Ibuprofen (600 mg)
Trial: 31101688
Drug: Neo‐adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo‐adjuvant chemotherapy (three cycles of platinum/paclitaxel chemotherapy)
Trial: 12565779
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine hydrochloride gel (Instillagel)
Trial: 8739937
Drug: Open reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open reduction and internal fixation using self-reinforced polyglycolide (SR-PGA) screws, poly-l-lactide (SR-PLLA) screw, small (SR-PGA) rods, and Kirschner-wires.
Trial: 8739937
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment followed by operation for removal of non-united fragment and reattachment of ligaments and muscles.